The phytotherapeutic drug sabal in benign prostate hyperplasia;Sabal, fytotherapeuticum bij benigne prostaathyperplasie: De zaagtandpalm schiet te hulp

Pharmaceutisch Weekblad

Volumn 134, Issue 18, 1999, Pages 647-651

  Horsten, S F A J ^a   Woerdenbag, H J ^a  

^a NONE

Author keywords

Fatty acids; Medicine, herbal; Pathology; Pharmacology; Phytosterols; Prostatic hypertrophy; Serenoa repens

Indexed keywords

DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; FRUIT; HORMONE ACTION; HUMAN; LIPOPHILICITY; PHYTOTHERAPY; PROSTATE HYPERTROPHY; REVIEW; SABAL;

EID: 0033532303     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Van der Kuy A, red. Farmacotherapeutisch Kompas 1998. Amstelveen: Ziekenfondsraad 1998.
2. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-40.
3. Bemoeilijkte mictie bij oudere mannen, NHG-Standaard M42, 1997. Rutten GEHM, Thomas S, red. NHG-Standaarden voor de huisarts, Utrecht: Nederlands Huisartsen Genootschap, 1997.
4. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379-95.
5. Tyler VE. The honest herbal, 3e ed. New York: Pharmaceutical Products Press, 1994:81-4.
6. Bombardelli E, Morazzoni P. Serenoa repens (Bartram) J.K. Small. Fitoterapia 1997;68:99-113.
7. Awang DVC. Saw palmetto, African prune and stinging nettle for benign prostatic hyperplasia (BPH). Can Pharm J 1997;130:37-40, 43-4, 82.
8. Fuchs U. Serenoa repens - Arzneipflanze mit Tradition und Zukunft bei der BPH. Z Phytother 1998;19:337-8.
9. Bruneton J. Pharmacognosy, phytochemistry, medicinal plants. Parijs: Lavoisier, 1995:143-4.
10. Shimade H, Tyler VE, McLaughlin JL Biologically active acylglycerides from the berries of saw-palmetto (Serenoa repens). J Nat Prod 1997;60:417-8.
11. Harnischfeger G, Stolze H. Serenoa repens-Die Sägezahnpalme. Z Phytother 1989;10:71-6
12. 14C]-β-sitosterol. Eur J Drug Metabol Pharmacokinet 1997;22:73-83.
13. Bracher F. Phytotherapie der benignen Prostathyperplasie. Urologe [A] 1997;36:10-7.
14. Weisser H, Tunn S, Behnke B, Krieg M. Effects of sabal serrulata extract IDS 89 and its subtractions on 5α-reductase activity in human benign prostatic hyperplasia. Prostate 1996;28:300-6.
15. Gutièrres M, Hidalgo A, Cantabrana B. Spasmolytic activity of a lipid extract from Sabal serrulata fruits: further study on the mechanism underlying its activity. Planta Med 1996;62:507-11.
16. 2 extracts of Serenoa repens fruits. Fitoterapia 1997;68:355-8.
17. Breu W, Hagenlocher M, Redl K, et al. Antiphlogistische Wirkung eines mit hyperkritischem Kohlendioxid gewonnenen Sabaifrucht-Ekstraktes. Arzneimittelforschung/Drug Res 1992;42:547-51.
18. Sultan C, Terraza A, Devillier C, et al. Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochem 1984;20:515-9.
19. Ravenna L, Di Silverio F, Russo MA, et al Effects of the liposterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate 1996;29:219-30.
20. Vacher P, Prevarskaya N, Skryma R, et al. The lipidosterolic extract from Serenoo repens interferes with prolactin receptor signal transduction. J Biomed Sci 1995;2:357-65.
21. El-Sheikh M, Dakkah MR, Saddique A. The effect of permixon on androgen receptors. Acta Obstet Gynecol Scand 1988;67:397-9.
22. 4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997;57:299-304.
23. Paubert-Braquet M, Cousse H, Raynaud JP, et al. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33:340-7.
24. Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy. Eur Urol 1992;21:309-14.
25. Tarayre JP, Delhon A, Lauressergues H, Stenger A. Anti-edematous action of an hexane extract from Serenoa repens Bartr. drupes. Ann Pharm Fr 1983;41:559-70.
26. Paubert-Braquet M, Richardson FO, Servent-Saez N, et al. Effect of Serenoo repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res 1996;34:171-9.
27. Casarosa C, Coscio di Coscio M, Fratta M. Lack of effects of a liposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. Clin Therap 1938;10:585-8.
28. Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994;26:247-52.
29. Von Vahlensick jr W, Fabricius PG, Hell U. Medikamentöse Therapie der benignen Prostathyperplasie. Fortschr Med 1996;114:407-11.
30. Weisser H, Behnke B, Helpap B, et al. Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur Urol 97;31:97-101.
31. Braeckmann J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 1994;55:776-85.
32. Romics I, Schmitz H, Frang D. Experience in treating benign prostatic hypertrophy with Sabal/serrulata for one year. Int Urol Nephrol 1993;25:565-9.
33. Kondás J, Philipp V, Diószeghy G Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol Nephrol 1996;28:767-72.
34. Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998;51:1003-7.
35. Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs placebo. Minn Urol Nefrol 1985;37:89-91.
36. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984;18:461-2.
37. Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995;48:97-103.
38. Newall CA, Anderson LA, Phillipson JD. Herbal medicines. A guide for health-care professionals. Londen: Pharmaceutical Press, 1994:237-8.
39. Lowe FC. Saw palmetto berry in the treatment of benign prostatic hyperplasia. Clin Res Reg Affairs 1997;14:53-66.